BioWorld Asia

Jan. 28, 2004

Two German Kinase Companies Merge, Bring In EUR11M Financing

MUNICH, Germany - Two young Munich biotechnology companies - Nadag AG and Sireen AG - merged to form Sirenade Pharmaceuticals AG, which will focus on oncology and central nervous system conditions. (BioWorld International) Read More

As GW's Sativex Is Reviewed, Extension-Study Data Grow

Detailed Inflammation Pathway Map To Hasten Drug Discovery

BresaGen Seeking Protection After Talks With Investor Fail

Denmark Eyes North Sea Oil Tax As Source For Research Funding

EU Aiming To Pave Way For Tissue-Engineering Market

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 29, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 29, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...